Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00093171 · ClinicalTrials.gov registry record · Phase 3
Study Evaluating rFIX; BeneFIX® in Hemophilia B
A Phase 3 study, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 23
- Enrollment target
NCT00093171 is a Phase 3 study that has completed, run by Wyeth is now a wholly owned subsidiary of Pfizer. The registered enrollment target is 23 participants.
The verdict
NCT00093171, a Phase 3 study, has completed, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 23 participants
- Enrollment target
Study Summary
The primary objective of this clinical research study is to assess the safety and efficacy of rFIX for a minimum of 6 months in previously treated patients (PTPs) with hemophilia B (FIX:C ≤2%) during standard-of-care treatment (on-demand, prophylaxis, and through major and minor surgical procedures).
Interventions
- DRUG rFIX
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Est. Completion | 2005-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00093171
The ClinicalTrials.gov registry entry for NCT00093171 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which rFIX is the first listed.
NCT00093171 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00093171 about?
NCT00093171 is a clinical study titled "Study Evaluating rFIX; BeneFIX® in Hemophilia B". The primary objective of this clinical research study is to assess the safety and efficacy of rFIX for a minimum of 6 months in previously treated patients (PTPs) with hemophilia B (FIX:C ≤2%) during standard-of-care treatment (on-demand, prophylaxis, and through major and minor surgical procedures)...
What is the current status of trial NCT00093171?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 23 participants. Estimated completion is 2005-05.
What interventions are being tested in trial NCT00093171?
The interventions under investigation include: rFIX (DRUG).
Who is sponsoring clinical trial NCT00093171?
This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.